Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Cadence presents positive top-line results from phase III Acetavance trial

Dec. 23, 2008

Neurobiological Technologies terminates further enrollment in clinical trials of Viprinex

Dec. 22, 2008

Bionomics successfully completes safety studies in animals of antianxiety drug BNC-210

Dec. 22, 2008

KeyNeurotek completes patient recruitment in phase IIa study of KN38-7271 in TBI

Dec. 22, 2008

New agents for psychiatric disorders described in recent Lilly and NeuroSearch patents

Dec. 19, 2008

Recent patents divulge novel analgesic agents

Dec. 19, 2008

Lundbeck initiates phase III trials with desmoteplase in ischemic stroke

Dec. 19, 2008

FDA accepts Transcept's Intermezzo NDA for review

Dec. 19, 2008

Adlea significantly reduces pain after total knee replacement in phase III trial

Dec. 19, 2008

Novel analgesic agents imparted in recent patent literature

Dec. 18, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...